Erythropoetin and iron preparations in the treatment of anemia in patients with chronic kidney disease of stage III-IV in systemic diseases

Terapevticheskii Arkhiv

Volumn 79, Issue 6, 2007, Pages 30-34

  Kozlovskaya, L V ^a   Milovanov, Yu S ^a   Nikolaev, A Yu ^a   Milovanova, L Yu ^a  

^a NONE

Author keywords

Chronic kidney disease; Erythropoietin; Nephrogenic anemia; Systemic diseases

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; IRON; IRON DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DOSE RESPONSE; ECHOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; IRON DEFICIENCY ANEMIA; MALE; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER; EPOETIN ALFA; FEMALE; FERRITINS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IRON; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34547624296     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Russian source
2. Hsu C. Y., McCulloch C. E., Curhan G. C. Epidemiology of anemia associated with chronic renal insuffiency among adults in the United States. J. Am. Soc. Nephrol. 2002; 13: 504-510.
3. Russian source
4. Furuland H., Linde T., Ahlmen J. et al. A randomized controlled trial of Hb normalisation with epoetin alfa in predialysis and dialysis patients. Nephrol. Dial. Transplant. 2003; 18: 353-361.
5. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am. J. Kidney Dis. 2001; 37: 182-238.
6. Russian source
7. Kuriyama S., Tomonari H., Yoshida H. et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure. Nephron 1997; 77: 176-185.
8. Russian source
9. Weiss G., Goodnough L. T. Anemia of chronic disease. N. Engl. J. Med. 2005; 352: 1011-1023.
10. Casadeval N., Nataf J., Viron B. et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with rhEPO. N. Engl. J. Med. 2002; 346: 469-475.
11. Azizi M., Rousseau A. Acute ACE inhibition increases the plasma level of natural stem cells regulator N-acetyl-seril-aspartyl-lisyl-proline. J. Clin. Invest. 1996; 97: 839-844.
12. Macdougall I. C. ACE inhibitors and erythropoietin responsiveness. Am. J. Kidney Dis. 2001; 38: 649-651.
13. Schiffle H., Lang S. M. ACE inhibitors, but not angiotensine II AT 1 receptor antagonists, affect etythropoiesis in patients with anemia of ESRD. Nephron 1999; 81: 106-108.
14. Bahmann F. H., Groot K., Holler H. Erythropoietin: is it more than correcting anaemia? Nephrol. Dial. Transplant. 2004; 19: 20-22.
15. Calo L. A., Davies P. A., Piccoli A. A role of heme oxygenase-1 in the antioxidant and antiapoptotic effects of rhEPO. Kidney Int. 2006; 69: 107-111.
16. Portoles J., Torralbo A., Martin P. et al. Cardiovascular effects of rhEPO in predialysis patients. Am. J. Kidney Dis. 1997; 29: 541-548.
17. Valderrabano F. Correction of anemia with rhEPO prevent of LV hypertrophy in predialysis patients. J. Am. Soc. Nephrol. 2000; 11: abstr. 0424.
18. Kausz A. T., Obrador G. T., Pereira B. J. Anemia management in patients with chronic renal insufficiency. Am. J. Kidney Dis. 2000; 36 (suppl. 3): S39-S51.
19. Kovesdy C. P., Trivedi B. K., Kalantar-Zadeh K. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006; 69: 560-564.
20. Levin A., Dourdoev O., Duncan J. Hb at time of referral prior of hemodialysis predicts survival: an association of Hb with long-term outcomes. Nephrol. Dial. Transplant. 2006; 21: 370-377.